Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

A Promyelocytic Leukemia Protein-Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma.

Dvorkina M, Nieddu V, Chakelam S, Pezzolo A, Cantilena S, Leite AP, Chayka O, Regad T, Pistorio A, Sementa AR, Virasami A, Barton J, Montano X, Lechertier T, Brindle N, Morgenstern D, Lebras M, Burns AJ, Saunders NJ, Hodivala-Dilke K, Bagella L, De The H, Anderson J, Sebire N, Pistoia V, Sala A, Salomoni P.

Clin Cancer Res. 2016 Jul 1;22(13):3398-409. doi: 10.1158/1078-0432.CCR-15-2081. Epub 2016 Apr 13. Erratum in: Clin Cancer Res. 2017 Feb 1;23 (3):870.

2.

Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells.

Chayka O, D'Acunto CW, Middleton O, Arab M, Sala A.

J Biol Chem. 2015 Jan 23;290(4):2198-212. doi: 10.1074/jbc.M114.624056. Epub 2014 Dec 4.

3.

Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications.

Corvetta D, Chayka O, Gherardi S, D'Acunto CW, Cantilena S, Valli E, Piotrowska I, Perini G, Sala A.

J Biol Chem. 2013 Mar 22;288(12):8332-41. doi: 10.1074/jbc.M113.454280. Epub 2013 Jan 28.

4.

Polyphenon [corrected] E enhances the antitumor immune response in neuroblastoma by inactivating myeloid suppressor cells.

Santilli G, Piotrowska I, Cantilena S, Chayka O, D'Alicarnasso M, Morgenstern DA, Himoudi N, Pearson K, Anderson J, Thrasher AJ, Sala A.

Clin Cancer Res. 2013 Mar 1;19(5):1116-25. doi: 10.1158/1078-0432.CCR-12-2528. Epub 2013 Jan 15. Erratum in: Clin Cancer Res. 2017 Jul 15;23 (14 ):3969. Clin Cancer Res. 2013 Apr 15;19(8):2273.

5.

Frizzled receptor 6 marks rare, highly tumourigenic stem-like cells in mouse and human neuroblastomas.

Cantilena S, Pastorino F, Pezzolo A, Chayka O, Pistoia V, Ponzoni M, Sala A.

Oncotarget. 2011 Dec;2(12):976-83.

6.

Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop.

Gualdrini F, Corvetta D, Cantilena S, Chayka O, Tanno B, Raschellà G, Sala A.

Oncotarget. 2010 Aug;1(4):278-88.

7.

Regulation of CLU gene expression by oncogenes and epigenetic factors implications for tumorigenesis.

Sala A, Bettuzzi S, Pucci S, Chayka O, Dews M, Thomas-Tikhonenko A.

Adv Cancer Res. 2009;105:115-32. doi: 10.1016/S0065-230X(09)05007-6. Review.

8.

Myb-induced chromatin remodeling at a dual enhancer/promoter element involves non-coding rna transcription and is disrupted by oncogenic mutations of v-myb.

Wilczek C, Chayka O, Plachetka A, Klempnauer KH.

J Biol Chem. 2009 Dec 18;284(51):35314-24. doi: 10.1074/jbc.M109.066175.

9.

Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread.

Bettuzzi S, Davalli P, Davoli S, Chayka O, Rizzi F, Belloni L, Pellacani D, Fregni G, Astancolle S, Fassan M, Corti A, Baffa R, Sala A.

Oncogene. 2009 Dec 10;28(49):4344-52. doi: 10.1038/onc.2009.286.

PMID:
19784068
10.

Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas.

Chayka O, Corvetta D, Dews M, Caccamo AE, Piotrowska I, Santilli G, Gibson S, Sebire NJ, Himoudi N, Hogarty MD, Anderson J, Bettuzzi S, Thomas-Tikhonenko A, Sala A.

J Natl Cancer Inst. 2009 May 6;101(9):663-77. doi: 10.1093/jnci/djp063. Epub 2009 Apr 28.

11.

C/EBPbeta induces chromatin opening at a cell-type-specific enhancer.

Plachetka A, Chayka O, Wilczek C, Melnik S, Bonifer C, Klempnauer KH.

Mol Cell Biol. 2008 Mar;28(6):2102-12. doi: 10.1128/MCB.01943-07. Epub 2008 Jan 14.

12.

Isolation and functional assessment of common, polymorphic variants of the B-MYB proto-oncogene associated with a reduced cancer risk.

Schwab R, Bussolari R, Corvetta D, Chayka O, Santilli G, Kwok JM, Ferrari-Amorotti G, Tonini GP, Iacoviello L, Bertorelle R, Menin C, Hubank M, Calabretta B, Sala A.

Oncogene. 2008 May 1;27(20):2929-33. Epub 2007 Nov 19. Erratum in: Oncogene. 2008 May 22;27(23):3360. Amorotti, G F [corrected to Ferrari-Amorotti, G].

PMID:
18026132
13.

A dual activation mechanism for Myb-responsive genes in myelomonocytic cells.

Yamkamon V, Ivanova O, Braas D, Chayka O, Patmasiriwat P, Klempnauer KH.

Blood Cells Mol Dis. 2008 Mar-Apr;40(2):219-26. Epub 2007 Oct 18.

PMID:
17950008
14.

v-Myb mediates cooperation of a cell-specific enhancer with the mim-1 promoter.

Chayka O, Kintscher J, Braas D, Klempnauer KH.

Mol Cell Biol. 2005 Jan;25(1):499-511.

Supplemental Content

Loading ...
Support Center